For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > BUSINESS
BUSINESS
- Otsuka’s H1 Pharma Sales Rise 12% on Global Brands, Profits Drop 26.2%
August 1, 2022
- Sumitomo’s Q1 Sales Zoom 22% on FX, Cancer Drug License Fee
August 1, 2022
- MSD Files 15-Valent Pneumococcal Vaccine for Pediatric Use in Japan
August 1, 2022
- Servier, Yakult to Wind Up Onivyde Promotion Deal in Japan
August 1, 2022
- Alnylam Japan Taps Ex-Galderma Chief Yutaka Okada as New President
July 29, 2022
- Shionogi Out-Licenses South Korea Rights of Cefiderocol to Local Firm
July 29, 2022
- Taiho Files Futibatinib for Biliary Tract Cancer Treatment in Japan
July 29, 2022
- Takeda to Lift Restricted Shipments for Leuplin in September after Over 2 Years
July 29, 2022
- JCR Files Growject for Short Stature due to SHOX Deficiency in Japan
July 29, 2022
- Takeda’s Q1 Sales Up 2.4% Despite Diabetes Divesture Last Year, Gets Hefty FX Gains
July 29, 2022
- Mochida to Quit Filgrastim Biosimilar as Repeated Price Cuts Made It Unprofitable
July 28, 2022
- Bayer, Employee Reach Settlement over Xarelto Scandal
July 28, 2022
- Kissei’s Global Plan for Fibroid Med Hits Snag as ObsEva Seeks Restructuring
July 28, 2022
- Ayumi to Curb Calonal Shipments amid Resurgence in COVID Cases
July 28, 2022
- GSK Japan Foresees 5% Annual Growth by 2026: President Lirette
July 28, 2022
- Horizon Japan Eager for Solo Sales of Its 1st Product as Tepezza Trial Likely to Wrap Up Next Year
July 27, 2022
- Padcev/Keytruda Combo Delivers Positive PIb/II Topline Data for Bladder Cancer: Astellas
July 27, 2022
- Shionogi Launches 4th-Dose COVID Jab Trial for Ages 60-Plus
July 27, 2022
- Mitsubishi Tanabe to Terminate Human Serum Albumin Business
July 26, 2022
- Enhertu Gets FDA’s Priority Review for HER2 Low Breast Cancer
July 26, 2022
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…